Post by ProductLife Group

𝗔 𝗿𝗶𝘀𝗸 𝗺𝗶𝗻𝗶𝗺𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝘁𝗵𝗮𝘁 𝗻𝗼𝗯𝗼𝗱𝘆 𝗳𝗼𝗹𝗹𝗼𝘄𝘀 𝗶𝘀 𝗻𝗼𝘁 𝗿𝗲𝗮𝗹𝗹𝘆 𝗮 𝗿𝗶𝘀𝗸 𝗺𝗶𝗻𝗶𝗺𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝗮𝘀𝘂𝗿𝗲. That is the uncomfortable truth behind a lot of pharmacovigilance work, and it was the focus of our recent webinar on 𝗥𝗶𝘀𝗸 𝗠𝗶𝗻𝗶𝗺𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗠𝗲𝗮𝘀𝘂𝗿𝗲𝘀, from the routine measures included in every product's information to the additional tools built for specific safety concerns, such as educational programmes, controlled access schemes or pregnancy prevention programmes. Choosing the right measure is only half the equation.  𝗧𝗵𝗲 𝗼𝘁𝗵𝗲𝗿 𝗵𝗮𝗹𝗳 𝗶𝘀 𝗽𝗿𝗼𝘃𝗶𝗻𝗴, 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗮𝗻𝗱 𝗼𝘂𝘁𝗰𝗼𝗺𝗲 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗼𝗿𝘀, 𝘁𝗵𝗮𝘁 𝗶𝘁 𝗶𝘀 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝘂𝗿 𝗶𝗻 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲. And that responsibility does not sit with one party alone: it is shared between Marketing Authorisation Holders and regulatory authorities throughout the measure's lifecycle. We have now turned those insights into an article. Matteo Berbeglia walks through the different types of RMMs, how Marketing Authorisation Holders and regulatory authorities share responsibility for getting them right, and 𝘄𝗵𝘆 𝗺𝗲𝗮𝘀𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗷𝘂𝘀𝘁 𝗮𝘀 𝗺𝘂𝗰𝗵 𝗮𝘀 𝗰𝗵𝗼𝗼𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗽𝗹𝗮𝗰𝗲.    📖 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://lnkd.in/eh47tZsF  🎥 𝗠𝗶𝘀𝘀𝗲𝗱 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿? 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴: https://lnkd.in/dacyFNmu     📩 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗼𝘂𝗿 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 to discuss your pharmacovigilance and risk management strategy: https://lnkd.in/eZaf8mQE     #ProductLifeGroup #Pharmacovigilance #RiskManagement #RMM #DrugSafety #RegulatoryAffairs #GVP #LifeSciences #PatientSafety